To apply this strategy to target two different tumour entities, non-small cell lung cancer (NSCLC) as well as Ewing sarcoma, a mesenchymal paediatric bone cancer, we have used our nanocarrier system with protamine-bound siRNA linked to the cancer cell-specific anti-EGFR-antibody cetuximab [6, 8] and the anti-insulin-like growth factor 1 receptor (IGF1R) antibodies cixutumumab and teprotumumab, respectively. Here, IGF1R is linked to non-small cell lung carcinoma.